Controversial FDA Approval Of Alzheimer’s Drug Aducanumab Sets Stage For Possible Medicare Coverage Battle Though CMS can't negotiate prices of Part B drugs like aducanumab, it has some discretion regarding coverage. Medicare Part B local carriers may balk, at least at broad coverage, pending results from the confirmatory trial Biogen is required to carry out to demonstrate aducanumab’s clinical benefit.